Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blobel, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blobel, G. A.
Related Collections
Right arrow Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, Vol. 95 No. 3 (February 1), 2000: pp. 745-755

REVIEW ARTICLE

CREB-binding protein and p300: molecular integrators of hematopoietic transcription

Gerd A. Blobel

From the Division of Hematology, Children's Hospital of Philadelphia, and the University of Pennsylvania School of Medicine, Philadelphia, PA.


    Introduction
Top
Introduction
Overview
Roles of CBP and...
CBP and p300 in...
Mechanisms of CBP and...
Summary and perspective
References

Differentiation of pluripotent hematopoietic stem cells into mature circulating blood cells is coordinated by a complex series of transcriptional events. During the last decade, numerous transcription factors have been identified whose expression is highly lineage-restricted within the hematopoietic system. These include the GATA family of transcription factors, NF-E2, EKLF, the C/EBP family of proteins, EKLF, and AML-1.1,2 However, tissue-specific and developmentally correct expression of a given gene is not achieved by a single transcription factor. Rather, unique combinations of cell-type specific and widely expressed nuclear factors account for the enormous specificity and diversity in gene expression profiles. Recently, 2 highly related and widely expressed molecules, CREB-binding protein (CBP) and p300, have emerged as important cofactors for a broad number of transcription factors both within and outside the hematopoietic system. Haploinsufficiency of CBP results in Rubinstein-Taybi Syndrome (RTS) in humans, a disease characterized by mental retardation, craniofacial abnormalities, broad toes and thumbs, and an increased propensity for malignancies, including those derived from the hematopoietic system.3 Mice heterozygous for a disrupted CBP gene display a phenotype similar to RTS,4 and have an increased incidence of leukemias and histiocytic sarcomas.5 Mice lacking both CBP alleles die during embryonic development and display severe defects in primitive and definitive hematopoiesis, and in vasculo-angiogenesis.6 Chromosomal translocations involving the CBP and p300 genes are associated with certain forms of leukemia, underscoring the importance of these genes in the regulation of hematopoietic cell differentiation and proliferation.

A series of recent reviews 7-9 serve as excellent guides through the large number of factors interacting with CBP and p300. This review will focus on the role of CBP and p300 in the transcriptional control of hematopoietic cell differentiation.

After a general overview of CBP and p300, the hematopoietic transcription factors regulated by CBP and p300 are described in a systematic fashion. Subsequently, human diseases involving the CBP and p300 genes and animal models related to these diseases are described. This is followed by an attempt to conceptualize our knowledge by discussing mechanistic aspects of CBP and p300 function.


    Overview
Top
Introduction
Overview
Roles of CBP and...
CBP and p300 in...
Mechanisms of CBP and...
Summary and perspective
References

CBP was originally discovered based on its ability to interact with the cAMP response element-binding protein (CREB),10 whereas p300 was isolated as a cellular target of the adenoviral oncoprotein E1A.11 Although E1A binds to various cellular proteins, including the Rb family of tumor suppressor proteins, its ability to block cell differentiation and to induce cell cycle progression in many cell types depends, at least in part, on its interaction with CBP and p300. The functions of CBP and p300 appear interchangeable in many published reports, yet both molecules also fulfill unique roles as revealed by gene inactivation studies.5,12,13

During the last 5 years, numerous transcriptional regulators have been found to interact with CBP and p300 (see Figure 1 for examples; for review see Shikama et al8). CBP and p300 are widely expressed and are believed to regulate gene expression in most cell types. Consistent with a function in a wide range of tissues, CBP-1, a C elegans factor closely related to CBP and p300, acts at an early stage in development and is essential for all non-neuronal differentiation pathways.14 In mammals, the situation is more complex because of the existence of at least 2 such molecules, CBP and p300.


View larger version (11K):
[in this window]
[in a new window]
  		Fig 1. Structure of CBP adapted from Shikama et al.8 Not all known CBP interacting proteins are shown. Amino acid numbers are approximate. HAT, histone acetyltransferase domain; CH, cysteine/histidine-rich region; BROMO, Bromodomain. Bromodomains are found in most histone acetyltransferases and in many chromatin-associated factors. Bromodomains specifically bind to acetylated lysine.167 CBP and p300 interact with tissue-specific (eg, MyoD), broadly expressed (eg, nuclear receptors), and general (eg, TFIIB and TBP) transcription factors. In addition, CBP and p300 interact with oncoproteins, including c-Jun and c-Fos, and tumor supressor proteins such as p53. CBP and p300 also interact with other HAT-containing molecules, such as p/CAF, SRC-1, and ACTR. Finally, CBP and p300 regulate the activity of signal-dependent transcriptional activators such as CREB and the STATs.

The complexity of protein-protein interactions surrounding CBP and p300 has led to their description as molecular integrators. Their ability to integrate multiple transcriptional signals is illustrated by the observation that many nuclear factors that interact with CBP and p300 can synergize with each other when bound to the same promoter in cis. On the other hand, inhibition between these factors might occur if they are bound to different promoters. Inhibition has been proposed to result at least in some cases from competition between these factors for limiting amounts of CBP and p300 in the nucleus.15,16 Genetic evidence for the idea that CBP and p300 are limiting stems from the discovery that patients who lack one allele of CBP suffer from RTS. Finally, normal development of Drosophila embryos is highly dependent on CBP gene dosage.17,18

Many of the protein interactions surrounding CBP and p300 are regulated by cellular signals. For example, phosphorylation of the transcription factor CREB regulates its interaction with CBP and p300, and hormones such as estrogens, glucocorticoids, and retinoic acid stimulate CBP and p300 binding to nuclear hormone receptors.

To add to the complexity, CBP and p300 can stimulate both the activating and repressive functions of certain nuclear factors. For example, although CBP and p300 increase p53 activity on certain p53-dependent promoters,19-21 they can also augment p53-mediated transcriptional repression on others.22 Moreover, CBP and p300 support cellular differentiation, but can also cooperate with gene products that interfere with it. Thus, promoter and cellular context are critical determinants of CBP and p300 function.

A breakthrough in the understanding of CBP and p300 function was the discovery that they act not only in a stoichiometric fashion, as is the case for most transcriptional cofactors, but that they also possess enzymatic activity. The laboratories of Bannister23 and Ogryzko Nakatani24 found that CBP and p300 possess intrinsic histone acetyltransferase (HAT) activity. Acetylation of histones is associated with a relaxed chromatin configuration, which is thought to facilitate transcription factor access to DNA. For example, work by Hebbes and colleagues25 demonstrated a strong correlation between the presence of acetylated core histones and DNase I sensitivity at the chicken beta -globin locus. DNase I sensitivity occurs before transcription is initiated and might reflect a state poised for transcriptional activation. The importance of a balance between the acetylated and nonacetylated state of histones in transcriptional regulation is supported by the discovery that certain transcriptional repressors are associated with histone deacetylases (for review see Pazin and Kadonaga26).

More recently, CBP and p300 have been shown to acetylate nonhistone nuclear proteins, including the tumor suppressor protein p53,27-29 dTCF,30 EKLF,31 GATA-1,32,33 NF-Y,34 the basal transcription factors TFIIE and TFIIF,35,36 and the architectural transcription factor HMG I(Y).37 In the case of p53, acetylation strongly increases DNA binding in vitro, providing a potential mechanisms for CBP and p300-mediated transcriptional control.27-29 Given the large number of factors that interact by CBP and p300, it is likely that some of these are also regulated by acetylation. Additional mechanisms by which CBP and p300 might operate are discussed later.


    Roles of CBP and p300 in hematopoiesis
Top
Introduction
Overview
Roles of CBP and...
CBP and p300 in...
Mechanisms of CBP and...
Summary and perspective
References

The viral oncoprotein E1A has been an invaluable tool for examining the requirements of CBP and p300 in gene expression and differentiation in various cell types. The N-terminus of E1A binds to dedicated domains within CBP and p300 and blocks their function.38,39 Indeed, in numerous studies, the first clues suggesting a requirement for CBP and p300 during gene regulation derived from experiments showing that forced expression of E1A, but not mutant forms of E1A defective for CBP and p300 binding, interfered with expression of certain myeloid, erythroid, and B-lymphocytic genes (Figure 3).

The following recurring themes are found in many of the studies summarized here. First, the activities of most transcription factors that interact with CBP and p300 are sensitive to coexpressed E1A. Inhibition by E1A is possible even if transcription factor binding occurs outside the E1A-binding domain of CBP and p300, suggesting that simple competition for CBP and p300 binding cannot account for all the effects of E1A. Second, stimulation of transcription factor activity by CBP or p300 usually ranges between 2-fold and 10-fold in transient transfection assays, indicating that CBP and p300 are limiting under these conditions. Third, various combinations of nuclear factors regulated by CBP and p300 synergize with each other when bound to the same promoter.

The following section is divided according to classes of CBP and p300-regulated hematopoietic transcription factors (summarized in Figure 2) rather than according to hematopoietic cell lineages, because most transcription factors are expressed in multiple cell types. Moreover, the biological functions of CBP and p300 in hematopoiesis are linked to the functions of the transcription factors with which they interact.


View larger version (9K):
[in this window]
[in a new window]
  		Fig 2. Structure of CBP indicating docking sites for hematopoietic transcription factors. See text for a detailed description of the listed factors. The domain(s) of CBP responsible for EKLF binding has not yet been determined. The observation that different factors interact with distinct domains of CBP might explain the transcriptional synergy observed between many of these factors.



View larger version (194K):
[in this window]
[in a new window]
  		Fig 3. Interference with CBP and p300 function in erythroid cells leads to a block in differentiation. MEL cells stably expressing a conditional, estradiol-dependent form of E1A were left untreated (U), or were treated with the differentiation-inducing agent DMSO (D), estradiol (E), or both (D/E). To monitor differentiation, cells were stained with benzidine, which stains hemoglobin (brown), and counterstained with May-Grunwald. Note the absence of benzidine-positive cells following estradiol-induced E1A activation (D/E). Control cell lines expressing mutant forms of E1A defective for CBP and p300 binding had no effect (not shown). For details, see Blobel et al.68

c-Myb

c-Myb is among the first hematopoietic transcription factors found to be regulated by CBP. c-Myb is the cellular counterpart of the v-Myb oncoprotein identified in the avian myeloblastosis virus (AMV). In the E26 virus, which causes mixed leukemia in chickens, v-Myb is part of a Gag-Myb-Ets fusion protein. Interestingly, Ets itself is regulated by CBP and p300 (see below). c-Myb expression is highest in progenitor cells of the myeloid, erythroid and lymphoid lineages and is downregulated during maturation/differentiation of these cells (for review see Weston40). Forced expression of c-Myb blocks differentiation of erythroid and myeloid cell lines.41-45 Expression of a dominant interfering form of c-Myb results in enhanced erythroid differentiation,46 whereas treatment with antisense oligonucleotides directed against c-Myb reduces proliferation of immature cells of the erythroid, myeloid and T-lymphoid lineages.47-49 Disruption of the c-Myb gene in mice leads to lethal anemia during fetal liver hematopoiesis.50 Along with the leukemogenic potential of c-Myb, the previously mentioned studies suggest that c-Myb functions in maintaining hematopoietic precursor cells in a proliferative state.

CBP was found to stimulate both c-Myb and v-Myb transcriptional activity in transient transfection experiments.51,52 c-Myb binds CBP in vivo and in vitro in a phosphorylation-independent manner at a site that overlaps with the CREB-binding domain of CBP. Expression of E1A, of antisense CBP RNA, or of dominant-negative CBP interferes with c-Myb-dependent transactivation.51,52 Although CBP moderately enhances c-Myb activity (approximately 3-fold), the presence of another CBP-regulated DNA binding protein such as NF-M, strongly increases the effects of CBP in a synergistic fashion.52

Given the requirement for CBP and p300 during differentiation of various cell types, it seems paradoxical that CBP would cooperate with gene products such as c-Myb or v-Myb that block differentiation. A possible explanation is that factors inducing differentiation and those stimulating proliferation compete for the action of CBP, depending on their expression levels during cellular maturation, or depending on cellular signals that regulate their interaction with CBP and p300.

The E2A proteins

Work from more than a decade ago demonstrated that E1A can repress the activity of the gamma 2b heavy chain (IgH) and the kappa light chain genes in lymphoid cells.53,54 However, at that time, the identity of transcription factors inhibited by E1A was unknown. Recent studies suggest that the basic helix-loop-helix (bHLH) proteins E47 and E12 might present critical targets for inhibition by E1A. E12 and E47, which are both encoded by the E2A gene (not to be confused with E1A), are essential regulators of B-cell gene expression. In most cell types, E12 and E47 proteins bind to DNA and regulate transcription as heterodimers with tissue-specific bHLH proteins, such as the hematopoietic transcription factor tal-1/SCL or the muscle-determining factors of the MyoD family. Remarkably, despite its broad distribution, only in B-cells can E47 bind DNA and activate gene expression as a homodimer.55 Targeted disruption of the E2A gene in mice leads to perinatal death and a selective ablation of mature B-cells.56,57 The cause of death is uncertain, but surprisingly, there are no obvious abnormalities present in other hematopoietic and nonhematopoietic tissues.56-58

Work by Eckner and colleagues59 demonstrated that p300 forms a stable complex with E47 on DNA. In addition, p300 stimulates E47 activity in transient transfection experiments by using a reporter gene driven by an intact IgH enhancer or by isolated E47-binding sites. p300 also interacts with bHLH proteins involved in myogenesis,59 suggesting that it has the capacity to target various members of bHLH protein superfamily that might include those involved in hematopoiesis. Along with the findings outlined later, this suggests a role for CBP and p300 in B-lymphoid gene expression.

GATA-1

GATA-1, one of the best studied hematopoietic transcription factors, is a zinc finger protein involved in the regulation of virtually all erythroid and megakaryocytic genes. GATA-1 is required for survival and maturation of primitive and definitive erythroid precursor cells.60-64 In addition, GATA-1 plays a critical role during megakaryocytic proliferation and differentiation.61,65 GATA-1 can trigger terminal differentiation and cell cycle arrest when reintroduced into a GATA-1-deficient immortalized proerythroblastic cell line.66

Among the genes regulated by GATA-1 are the globin genes, which, in turn, are under the influence of the locus control regions (LCRs). The LCRs, which contain multiple functionally important GATA-binding sites, are thought to act in part by regulating the chromatin structure at the globin gene loci.67 Given that CBP has histone acetyltransferase activity, it is noteworthy that GATA-1 interacts with CBP in vivo and in vitro.68 This interaction involves the zinc finger region of GATA-1 and the E1A-binding domain of CBP. CBP strongly augments GATA-1 activity in transient expression assays.68 Expression of E1A in the erythroid cell line MEL leads to a complete block in differentiation and to reduced expression of GATA-1-dependent genes, including the alpha - and beta -globin genes (Figure 2).68 These findings are consistent with a mechanism by which CBP and p300 mediate at least some functions of GATA-1 in intact erythroid cells.

Other GATA factors, including GATA-2 and GATA-3, which have distinct expression patterns in hematopoietic cells, are also stimulated by CBP (G. A. Blobel, unpublished). GATA-2 levels are high in progenitor cells and decline during erythroid maturation.69,70 In contrast, GATA-1 levels increase as cells mature.69,70 Thus, it is possible that as its levels rise, GATA-1 recruits CBP away from factors required for proliferation of precursor cells such as GATA-271 and c-Myb,50 using them for the activation of differentiation-specific genes.

One mechanism by which CBP regulates GATA-1 activity appears to involve direct acetylation of GATA-1 itself. Two reports showed that CBP and p300 acetylate GATA-1 at 2 highly conserved lysine rich motifs near the zinc fingers.32,33 In addition, CBP stimulates acetylation of GATA-1 in vivo at the same sites acetylated by CBP in vitro.33 In vivo acetylation of GATA-1 by CBP is inhibited by E1A but not by mutant E1A defective for CBP and p300 binding,33 establishing a correlation between acetylation of GATA-1 and its transcriptional activity. Although Boyes et al32 reported that acetylation by p300 stimulates DNA binding of chicken GATA-1 in vitro, no change in DNA binding upon acetylation was observed by Hung et al.33 This discrepancy may be the result of using chicken GATA-1/p300 versus murine GATA-1/CBP, respectively. However, several lines of evidence suggest that changes in DNA binding might not be the mechanism by which acetylation regulates GATA-1 activity in vivo. First, mutations in the acetylation sites do not affect DNA binding of mammalian expressed GATA-1 molecules but do affect the transcriptional response to CBP and p300.32,33 Second, although CBP and p300 stimulate GATA-1 activity in transient transfection assays, no evidence exists showing that this stimulation is associated with an increase in DNA binding of GATA-1. Third, when assayed in the context of differentiating erythroid cells, mutations in either of the 2 acetylation motifs impair the ability of murine GATA-1 to trigger erythroid differentiation without affecting its ability to bind DNA.33 This indicates that the biological activity of the acetylation sites can be uncoupled from their putative role in DNA binding.

Although acetylation of GATA-1 is likely to be important for GATA-1 function in vivo, the underlying molecular mechanism remains to be determined. Acetylation of GATA-1 does not affect its interaction with Fog, CBP, or GATA-1 itself.33 However, it is possible that acetylation leads to changes in the conformation of GATA-1 or affects interaction with other as yet unidentified cofactors. The acetylation motifs of GATA-1 might serve as docking sites for interaction with such cofactors.

NF-E2

Given the large number of CBP-interacting proteins, it is likely that the strong inhibitory effects of E1A on MEL cell differentiation and globin gene expression might involve multiple CBP-interacting factors. Indeed, a very recent report showed that NF-E2 binding sites in the LCR are important in mediating E1A sensitivity of the beta -globin LCR.72 Moreover, both NF-E2 and EKLF (see below), have been reported to physically interact with CBP. The basic zipper (bZip) transcription factor NF-E2 is composed of a hematopoietic-restricted p45 subunit and a widely expressed p18 subunit, which is a member of the maf family of proteins73-75 (for review see Blank and Andrews76). Other p45-related molecules capable of interacting with maf family members include Nrf1, Nrf2, Nrf3, Bach 1, and Bach 2 (for references see Kobayashi et al77). Multiple functionally important NF-E2-binding sites are present in the alpha - and beta -globin LCRs. Loss of a functional p45 gene leads to a pronounced defect in platelet formation,78 whereas globin gene expression and erythroid development are only mildly affected.79 This suggests that other members of the p45 family might substitute for p45 function in erythroid cells.

In vitro binding experiments showed that the p45 subunit of NF-E2 binds directly to CBP.80 This study further suggests that CBP might participate in mediating the ligand-dependent stimulation of the thyroid hormone receptor by p45. This is of biologic interest given the role of thyroid hormone during erythropoiesis.81 Although the functional and molecular consequences of the p45-CBP interaction have not been studied in detail, it is conceivable that NF-E2 cooperates with GATA-1 and EKLF in the formation at the LCR of a high molecular weight transcription factor complex (enhanceosome) surrounding CBP and p300.

It is important to point out that NF-E2 activity on chromatinized templates cannot be attributed solely to the recruitment of histone acetyltransferases. A report by Armstrong and Emerson82 demonstrated that NF-E2 can disrupt chromatin structure on templates containing regulatory regions of the beta -globin locus, and that the NF-E2-associated chromatin modifying activity is ATP-dependent.

EKLF

Another transcription factor regulated by CBP is the zinc finger-containing erythroid Krüppel-like factor EKLF.83 EKLF is specifically required for the expression of adult beta -globin but not alpha -globin genes, and loss of EKLF function leads to lethal beta -thalassemia in mice.84,85 Moreover, EKLF -/- mice carrying a human globin gene locus display a delayed gamma - to beta -globin switch that normally occurs at the onset of adult bone marrow erythropoiesis.86,87 Interestingly, absence of EKLF also results in a loss of DNase 1 hypersensitive site formation at both the transgenic and endogenous beta -globin promoters,87 consistent with a role of EKLF in remodeling chromatin at these promoters.

EKLF can interact with both CBP and p300, and the CBP- and p300-associated acetyltransferase p/CAF in transfected cells. However, CBP and p300, but not p/CAF, acetylate EKLF in vitro.31 Acetylation most likely occurs at 2 residues that are part of an inhibitory domain adjacent to the zinc finger region. Metabolic labeling experiments that used [3H]acetate further suggest that EKLF is acetylated in vivo.31 CBP and p300, but not p/CAF, stimulate EKLF activity in transient transfection experiments that used the erythroleukemia cell line K562.31 It will be interesting to determine whether acetyltransferase activity of CBP and p300 is required for stimulation of EKLF activity. Acetylation did not affect DNA binding of EKLF, and the molecular consequences of acetylation are not yet known.31

Together, the above reports suggest that erythroid transcription factors controlling globin gene expression might cooperate in the formation of a high molecular weight complex in which GATA-1, NF-E2, and EKLF are linked through CBP and p300 (Figure 4). Consistent with such a model is the observed synergy between GATA-1 and EKLF in transactivation experiments.88


View larger version (29K):
[in this window]
[in a new window]
  		Fig 4. Hypothetical model in which NF-E2, GATA-1, and EKLF cooperate to recruit CBP and p300 to the locus control region of the beta -globin gene cluster. This could lead to acetylation of nearby histones and transcription factors. Acetylation of histones leads to changes in chromatin structure, and acetylation of transcription factors might stabilize their interaction with DNA or alter their transcriptional activity. It is conceivable that this high molecular weight complex also connects to the promoters of the globin genes through a looping mechanism.

C/EBP

CCAAT-box/enhancer binding proteins (C/EBPs) belong to the basic region/leucine zipper class of transcription factors and play a role in the differentiation of a broad range of tissues. In the hematopoietic system, C/EBP family members are expressed mostly in the myelomonocyctic lineage and participate in the regulation of macrophage and granulocyte-restricted genes, such as the M-CSF receptor, G-CSF receptor, and GM-CSF receptor genes (for review see Lekstrom-Himes and Xanthopoulos, and Yamanaka et al89,90). Targeted disruption of the C/EBPd, C/EBPbeta , or C/EBPepsilon genes resulted in defects predominantly affecting the granulocytic lineage,91-94 whereas other hematopoietic lineages remained intact. C/EBP transcription factors are also critical mediators of inflammatory and native immune functions (for review see Poli95).

Studies by Mink et al96 showed that C/EBPbeta -dependent transcription is E1A-sensitive and that overexpressed p300 stimulates C/EBPbeta activity on the macrophage/granulocyte-specific mim-1 promoter and, importantly, also on an endogenous C/EBP-regulated gene, called 126. Moreover, p300 increases the synergy between c-Myb and C/EBPbeta . C/EBPbeta  binds to the E1A-binding region of p300 through its N-terminus. Overexpression of the minimal C/EBPbeta -binding domain of p300 reduced the activity of C/EBPbeta  presumably by interfering with the C/EBPbeta -p300 interaction.96 The N-terminus of C/EBPbeta contains stretches of amino acids conserved among C/EBP family members suggesting that other C/EBP molecules might also be regulated by CBP and p300.96 Together, these results implicate CBP and p300 as important cofactors during granulocytic gene expression.

Ets

The Ets family of transcription factors is a diverse group of approximately 30 proteins that share a conserved DNA binding domain.97 The c-ets-1 proto-oncogene is transduced by the E26 avian acute leukemia virus to form part of the Gag-Myb-Ets gene fusion. This virus induces both erythroid and myelomonocytic leukemias. Full transforming activity of E26 requires the presence of both the Myb and Ets portions of the fusion protein.98,99 Ets-1 is expressed predominantly in lymphoid cells and regulates a number of lymphocyte-specific genes. Gene knockout studies demonstrated a role for Ets-1 in T-cell proliferation and survival.100,101 Effects on B-cell differentiation were also observed.100,101 Ets-1 and some of its relatives synergize with a number of transcriptional regulators known to interact with CBP and p300, such as AP-1,102 and Myb.103-106 Especially striking is the frequently observed cooperativity between Ets-like factors and GATA-1 during the expression of several megakaryocyte-restricted genes, including the alpha IIb,107 GPIX,108 GP1balpha ,109 the thrombopoietin receptor (c-mpl),110 and PF4 genes.111 The synergy of Ets proteins with CBP and p300-regulated factors led to the hypothesis that they too are regulated by CBP. Indeed, Yang et al112 showed that the Myb- and Ets-dependent promoter of the myeloid-expressed gene CD13/APN is sensitive to the expression of E1A but not mutant E1A defective for CBP and p300 binding. Ets-1 activity is stimulated by coexpressed CBP, and Ets-1 associates with CBP in nuclear extracts. In vitro, the N-terminus of Ets-1 can form 2 contacts with CBP involving the CH1 and CH3 domains of CBP. In support of the functional importance of the physical interaction between Ets-1 and CBP, the authors demonstrated a good correlation between binding of Ets-1 to the CH1 region and its ability to transactivate. In addition, Ets-1 coprecipitates with histone acetyltransferase activity, consistent with its association with CBP and p300 and/or other acetyltransferases in vivo.112

Of note, another Ets family transcription factor, PU.1, was recently found to interact with CBP through the activation domain of PU.1 in a yeast 2-hybrid assay.113 CBP stimulates PU.1 transcriptional activity in transient transfection assays. PU.1 is specifically expressed in hematopoietic organs with the highest levels detected in myeloid and lymphoid cells.114 Thus, CBP and very likely p300 target a broad range of myeloid and lymphoid expressed transcription factors.

AML1

Another leukemogenic transcription factor controlled by p300 is AML1.115 The AML1 gene is rearranged in several distinct chromosomal translocations associated with acute myeloid leukemia (AML; t[8;21]), acute lymphatic leukemia (ALL; t[12;21]), and myelodysplastic syndrome (t[3;21]) (for review see Look116). The AML1 gene is the most frequent target for chromosomal translocations in human leukemias. AML1 constitutes a family of at least 3 factors derived from the same gene by alternative splicing. The AML1 gene products bind to DNA as heterodimeric complexes with CBFbeta . Of note, the CBFbeta gene itself is involved in chromosomal rearrangements found in cases of AML.116 Consistent with its broad expression pattern and the presence of functionally important AML1 binding sites in the promoters and enhancers of myeloid and lymphoid expressed genes, knock-out studies revealed that both AML1 and CBFbeta genes are essential for the formation of all definitive blood lineages.117-121

AML1b, one of the AML1 isoforms containing an activation domain, and p300 associate in vivo and in Far Western blots, and p300 stimulates AML1b activity on the myeloperoxidase promoter in transient transfection experiments.115 Overexpression of the t(8;21) translocation product AML1-ETO in the IL-3-dependent myeloid cell line L-G interferes with G-CSF-induced differentiation along the neutrophilic lineage. Forced expression of wild-type AML1b can overcome the effects of AML1-ETO and restore differentiation.115 In contrast, AML1a, which lacks an activation domain, is inactive in this assay. The potential of various AML1b constructs to induce differentiation is further enhanced by coexpression of p300 and correlates well with their ability to interact with p300.115 This indicates that p300 plays a role in myeloid cell differentiation and suggests that the rearranged AML genes found in chromosomal translocations act as dominant negative alleles. The latter notion is consistent with the recent finding that AML-ETO associates with a transcriptional repressor complex containing histone deacetylases and that this deactylase complex is required for blocking differentiation of myeloid cells.122-124 This raises the interesting possibility that the intrinsic (or associated) acetyltransferase activity of p300 might be required to overcome the repressive effects of AML-ETO. Indeed, a truncated form of p300 lacking the acetyltransferase domain was impaired in its ability to synergize with AML-1b. However, a more detailed mutagenesis of p300 will be required to establish a correlation between its HAT activity and its ability to cooperate with AML1b.

Finally, AML-1 synergizes with c-Myb and with C/EBP on myeloid and lymphoid promoters.125-127 This synergy is apparently not the result of cooperative DNA-binding,127,128 suggesting that it is instead mediated through recruitment of a common cofactor such as CBP and p300, similar to what has been proposed for other CBP and p300 regulated factors.


    CBP and p300 in leukemia-associated chromosomal translocations
Top
Introduction
Overview
Roles of CBP and...
CBP and p300 in...
Mechanisms of CBP and...
Summary and perspective
References

Both CBP and p300 bind the viral oncoproteins E1A and SV40 T. This raised the possibility that alterations in the functions of CBP and p300 might play a role in the development of malignancies in humans. This suspicion was supported by the finding that 1 copy of the CBP gene is inactivated in the rare disease Rubinstein-Taybi syndrome,3 which is manifested by an increased propensity for tumors (mostly of the nervous system), craniofacial malformations, and mental retardation.129,130

The involvement of CBP and p300 in hematologic malignancies was realized through the discovery of leukemia-associated chromosomal translocations involving the CBP and p300 genes. These translocations generally result in fusion products that preserve most of the CBP and p300 molecules, suggesting that the disease mechanism does not simply involve loss of function of CBP, as is the case in Rubinstein-Taybi syndrome. Instead, they suggest altered function (dominant positive or dominant negative) through fusion to another molecule. For example, AML-derived leukemic blast cells containing the t(8;16)(p11;p13) translocation, which is often associated with acute myelogenous leukemia subtype M4/M5, have the CBP gene fused to the MOZ (monocytic leukemia zinc finger) gene.131 This fusion results in a small deletion of the N-terminal 266 amino acids of CBP leaving the rest of the molecule intact.131 Interestingly, the MOZ gene also has a putative acetyltransferase domain that is retained in the MOZ-CBP fusion.

In principle, any translocation event could lead to gain or loss of function of either fusion partner, to the formation of dominant interfering alleles, or to entirely new activities. Fusion of CBP to a given transcription factor might result in aberrant recruitment of CBP to certain promoters, leaving less free CBP available for other transcription factors involved in balancing proliferation and differentiation. In addition, it is possible that misdirected or deregulated acetyltransferase activity by CBP and p300 fusion products causes changes in gene expression profiles that contribute to the transformed state. One likely mechanism by which the MOZ-CBP fusion contributes to malignant transformation involves constitutive recruitment of CBP to MOZ-regulated genes. The MOZ gene contains 2 C4HC3 zinc finger regions, also found in CBP and p300, and a C2HC zinc finger. These regions might serve as protein-protein interaction domains and might target MOZ to chromatin-associated proteins and DNA.131 The MOZ-CBP fusion protein contains the CBP-derived and the putative MOZ acetyltransferase domain that together could be powerful regulators of chromatin structure and transcriptional activity at MOZ-regulated genes.

Since their initial discovery, additional cases of AML with t(8;16) translocations resulting in CBP and MOZ gene arrangements have been reported.132 However, in these cases no MOZ-CBP fusion transcripts were detected, raising the possibility that CBP or MOZ gene rearrangements might contribute to leukemogenesis by alternative mechanisms.

Another clinically relevant example of the importance of balancing histone acetylation and deacetylation comes from studies of acute promyelocytic leukemia (APL)-associated translocations that fuse the retinoid acid receptor alpha (RARalpha ) to the PLZF or PML genes. PML-RARalpha and PLZF-RARalpha fusion proteins have a high affinity for a transcriptional repressor complex containing histone deacetylases. Although normal RAR responds to retinoic acid (RA) by shedding the deacetylase complex, followed by association with an acetyltransferase complex (which contains CBP), PML-RARalpha responds only to very high concentrations of RA, and PLZF-RARalpha is RA resistant.133-135 The ability of leukemic cells to differentiate upon RA treatment correlates with the ability of their translocation fusion proteins to displace the repressor complex in response to RA. In fact, patients with PML-RARalpha APL typically achieve remission upon treatment with high doses of RA, whereas PLZF-RARalpha APL patients do not.

The chromosomal translocation, t(11;16), which is associated with therapy-induced acute myeloid leukemia, therapy-induced chronic myelomonocytic leukemia, and myelodysplastic syndrome, fuses the MLL and CBP genes such that most of the CBP molecule stays intact.136-139 The MLL gene was also found to be fused to the p300 gene in an AML patient carrying a t(11;22) translocation.140 The MLL gene encodes a large multidomain protein containing zinc fingers and AT-hook motifs,141-143 and is involved in translocations with at least 40 different fusion partners (for references see Sobulo et al137). This raises the question whether the structural alterations of MLL itself or of its fusion partners are critical for leukemogenesis. Together, these findings underscore the importance of CBP and p300 function in balancing growth and differentiation of hematopoietic cells.


    Mechanisms of CBP and p300 function
Top
Introduction
Overview
Roles of CBP and...
CBP and p300 in...
Mechanisms of CBP and...
Summary and perspective
References

Clues from studies of intact animals. Some unexpected insights into the function of CBP and p300 have come from gene knock out studies. The CBP and p300 null mice display similar phenotypes.13 The p300-/- embryos die between days 9 and 11.5. Their main defects are severe developmental retardation, reduced size, failed neural tube closure, and altered cardiac ventricular trabeculation. A fraction of the p300 +/- mice die early, displaying neural tube closure defects similar to the p300-/- mice, indicating a requirement for full p300 gene dosage during neural development. Mice heterozygous for CBP deficiency suffer from skeletal abnormalities and growth retardation, a phenotype resembling RTS in humans.4 CBP and p300 compound heterozygous mice die early and display a phenotype very similar to the individual homozygous knock outs.13

More extensive analysis of mice heterozygous for CBP deficiency revealed defects in the hematopoietic system that only became apparent in newborn pups beginning at 3 months of age.5 The CBP +/- animals have extramedullary myelopoiesis and erythropoiesis, and display enlarged, hypercellular spleens. In the peripheral blood, the most striking defect is a decrease in the number of B-lymphocytes, whereas in the bone marrow, cells of the erythroid, myeloid, and B-lymphocytic lineage were significantly reduced. No overt malignancies were observed in the CBP +/- mice until the mice reached at least 1 year of age. Then, 4 of the 18 mice analyzed had overt tumors, 2 had histiocytic sarcomas, 1 had myelomonocytic leukemia, and 1 had lymphocytic leukemia. In light of the small number of cases studied, it is conceivable that other types of hematologic neoplasms might occur at an increased rate in CBP +/- mice. When splenocytes or bone marrow cells from apparently tumor-free CBP+/- donors were engrafted into sublethally irradiated wild-type mice, the recipients developed histiocytic sarcomas at a high rate with latency periods of 3 to 5 months. Grafts derived from 1 CBP +/- donor resulted in the formation of plasmacytomas with monoclonal gammopathy and renal amyloid deposition. DNA analysis of 1 plasmacytoma and 1 histiocytic sarcoma from bone marrow-transplanted mice revealed the specific loss of the wild-type CBP allele with retention of the targeted one. Loss of heterozygosity in these cases suggests that CBP is a tumor supressor gene, similar to the RB family of proteins that are also targeted by the E1A oncoprotein. Surprisingly, no hematologic defect or cancer predisposition was observed in age- and strain-matched p300 targeted mice.5 This suggests that, despite their similarity, CBP and p300 might play distinct roles in certain cell types.

The tumors observed in CBP +/- in mice appear to be restricted to the hematopoietic system, although additional types of neoplasms might be found as more mice are analyzed. In contrast, patients with RTS have an increased risk for tumors of various origins, the most common tumors being neurally derived. Hematologic malignancies observed in RTS patients occur less frequently and include acute lymphocytic leukemia, acute myelogenous leukemia, and non-Hodgkin lymphoma.130

A very recent report describes the hematologic consequences of homozygous CBP-deficiency in mice.6 In this study, disruption of the CBP gene resulted in the formation of a truncated form of CBP that retains the N-terminal 1084 amino acids (of 2441) but lacks the HAT domain. Mice homozygous for this defect die between day 9.5 and 10.5 of embryogenesis similar to the CBP knock-out mice. Before their deaths, embryos are anemic, and their yolk sacs contain fewer erythroid cells and display a defective vascular network. Although the number of yolk sac-derived erythroid colony forming units is reduced, a few mature erythroid cells are found, suggesting that CBP is not absolutely required for erythroid maturation and that p300 might be able to partially compensate for the CBP defect. To examine definitive hematopoiesis in the CBP -/- mice, organ culture was performed from E9.5 embryos with tissue from the aorta-gonad-mesonephros (AGM) region, followed by colony forming assays. These experiments revealed dramatically reduced numbers of definitive erythroid and granulocyte/macrophage progenitor cells. Organ cultures from these embryos also revealed a strong reduction in vasculo-angiogenesis.

The mechanisms by which CBP deficiency cause RTS in humans and the severe hematologic and nonhematologic defects in mice are entirely unknown. The answer to this question is complicated by the enormous complexity of protein interactions surrounding CBP and the multitude of mechanisms by which CBP regulates gene expression. Analysis of gene expression profiles in tissues from CBP-deficient mice, as well as gene complementation experiments with mutant CBP gene constructs, could be used to tackle this question. Progress in the understanding of the phenotypic defects that result from CBP deficiency requires a reductionistic approach involving the study of individual CBP- and p300-binding transcription factors and the genes that they control. For example, it is conceivable that the reduced number of B lymphocytes in CBP +/- mice results from reduced activity of the E47 transcription factor that interacts with CBP and p300, and that is required for B-cell development.59

Strength in numbers. CBP and p300 interact with numerous transcription factors. Many of these interactions might take place simultaneously because they are mediated by distinct domains. This could account for the observed synergy between factors regulated by CBP. Thus, CBP might provide a platform for the assembly of high molecular weight complexes (enhanceosomes; for review see Carey144) containing multiple DNA-binding proteins that position the complex in a sterically correct fashion at promoters and enhancers. Because this complex is likely to include non-DNA-binding proteins such as p/CAF, ACTR, or SRC-1, which also possess acetyltransferase activity, it would constitute a powerful regulator of chromatin structure.145-147 For example, a high molecular weight complex centered on CBP and p300 could form at the LCR, which participates in regulating chromatin structure at the beta -globin locus (Figure 4). The LCR contains binding sites for GATA-1, EKLF, and NF-E2 all of which bind to CBP and p300.31,33,68,80 Thus, CBP and p300 might integrate signals from multiple transcriptional regulators and perhaps even present targets for global regulators of gene expression, such as signaling cascades used by growth/differentiation factors. The latter notion is supported by the observation that CBP and p300 are acetylated and phosphorylated.

CBP and p300 are also thought to mediate negative cross-talk between transcription factors. Competition for limiting amounts of CBP and p300 has been invoked to account for mutual inhibition of CBP- and p300-regulated transcription factors when bound to separate DNA templates.15 This might explain the inhibition of GATA factors by ligand-activated nuclear hormone receptors (NR).148-150 The observation that overexpression of CBP alleviates NR-mediated repression of GATA-1, and that ligand-bound NR reduce the stimulation of GATA-1 activity by CBP (G. A. Blobel, unpublished) are consistent with such a model. Together, these findings support a role of CBP and p300 as molecular integrators of positive and negative transcriptional signals that govern hematopoietic gene expression.

Building a bridge. The large number and diversity of genes and transcription factors regulated by CBP and p300 could be explained if CBP and p300 were components of the basal transcription apparatus. In support of such a model, CBP and p300 have been found to interact with TFIIB,151 TBP,152-155 and RNA polymerase II.156-160 Thus, recruitment of CBP by a DNA-bound transcription factor could facilitate the formation of a preinitiation complex at relevant promoters (Figure 5). Such a mechanism would imply that CBP and p300 act in a stoichiometric fashion. Although this might be true on some promoters, additional evidence suggest that CBP and p300 also act catalytically (see next paragraph).


View larger version (24K):
[in this window]
[in a new window]
  		Fig 5. Hypothetical model in which CBP and p300 link DNA-bound nuclear factors to components of the basal transcription machinery. GTFs, general transcription factors; TBP, TATA-binding protein, Pol II, RNA polymerase II.

Action by catalysis. The observation that CBP, p300, and some of its associated factors possess acetyltransferase activity suggests an enzymatic mechanism of gene regulation. Targeting of CBP and p300 to the appropriate sites could lead to local increases in histone acetylation, followed by rearrangement of chromatin structure (Figure 4). This in turn could favor access of other transcriptional regulators. Again, the LCR provides an example where such a mechanism might be operating. As previously mentioned, histone acetylation and open chromatin correlate well at the chicken beta -globin gene locus.25 However, depending on transcription factor/promoter context, CBP and p300 can also act in a HAT-independent fashion.161

If some nuclear factors act by recruiting a histone-modifying enzyme to trigger chromatin opening, how do they find access to DNA in the first place? One possibility is that other transcription factors might pave their way by opening chromatin structure in an acetylation-independent fashion. An example for such a scenario is provided by the observation that NF-E2 disrupts chromatin structure in a ATP-dependent manner on a chromatinized template containing DNase1 hypersensitive site 2 of the beta -globin LCR.82 This leads to increased access of GATA-1 to adjacent GATA sites.

Alternatively, GATA-1 might find access to chromatin without the assistance of other factors. A recent report162 demonstrated that chicken GATA-1, or a peptide comprising just its DNA-binding domain, can bind to DNA packaged into a nucleosome. This leads to a reversible breakage of histone/DNA contacts, thus perturbing nucleosome structure.162 Once bound to DNA, the GATA-1-associated acetyltransferase complex might modify adjacent histones, thus facilitating access of other transcription factors to DNA.

It is important to keep in mind that modification of chromatin is not restricted to acetylation, and that numerous regulated chromatin modifying complexes have been identified (for review see Kadonaga163). For example, an elegant study by Armstrong et al164 demonstrated that EKLF interacts with a complex, called E-RC1, which contains components of the mammalian SWI/SNF complex, an ATP-dependent chromatin remodeling machine.163 However, E-RC1 does not appear to contain histone acetyltransferases (Beverly Emerson, personal communication).

Acetylation of nonhistone proteins, including transcription factors, might turn out to be of equal importance for CBP and p300 function. For example, acetylation of p53 leads to an increase in DNA binding activity.27-29 It is likely that acetylation regulates transcription factor activity by a variety of mechanisms. In the case of the drosophila transcription factor dTCF, acetylation by CBP decreased its affinity for its cofactor beta -catenin/Armadillo, leading to transcriptional inhibition.30 An interesting variation of this theme is the finding that acetylation of the architectural transcription factor HMG)-I(Y) by CBP leads to destabilization of an enhanceosome complex at the interferon gamma  gene promoter, resulting in termination of transcription.37

It is conceivable that acetylation might be a widely used mechanism to trigger allosteric changes in proteins, thereby regulating protein-protein and protein-DNA interactions, similar to what has been observed upon protein phosphorylation. In both cases, the modification results in a change of charge, addition of a negative charge in the case of phosphorylation, and neutralization of a positive charge in the case of acetylation. Moreover, acetylation changes the size of the lysine side chain, which could be important in protein folding.


    Summary and perspective
Top
Introduction
Overview
Roles of CBP and...
CBP and p300 in...
Mechanisms of CBP and...
Summary and perspective
References

CBP and p300 are large, multifunctional molecules that can exert both positive and negative effects on transcription and cell differentiation. It is likely that additional factors will be discovered to interact with CBP and p300, and that a subset of these might be regulated by acetylation. The challenge that lies ahead will be to determine the significance of such interactions in physiologically relevant settings. Given that CBP and p300 share many functions this will not be an easy task, especially because it has not been possible so far to generate CBP and p300 double knock-out cell lines. The mechanisms by which CBP and p300 act likely depend on promoter and cellular context as well as the chromatin configuration in which a given target gene is embedded. One approach that would allow dissection of CBP and p300 functions in a physiologic context would be to knock in mutant CBP and p300 alleles bearing mutations in domains associated with specific functions such as the HAT domain or important protein docking sites. Such experiments might also yield insights into the mechanism by which loss of CBP leads to RTS.

Given the broad variety of CBP and p300 regulated factors, an important and challenging task will be the identification of the relevant downstream target genes that mediate their function in vivo. Subtractive hybridization and microarray technologies might be useful approaches to identify genes most sensitive to changes in CBP and p300 levels.

Although CBP and p300 are expressed in most tissues, their importance in regulating gene expression and differentiation in hematopoietic cells is illustrated by their involvement in leukemia-associated chromosomal translocations. It remains to be determined why these chromosomal translocations result in leukemias mostly of the myeloid/monocytic lineage.

Because CBP and p300 have intrinsic and associated acetylase activity, they might present targets for pharmacological intervention. It can be envisioned that novel drugs might be developed that alter their specific activity or substrate specificity, thereby allowing for modulation of gene expression and cell differentiation. For example, in cases in which CBP acetyltransferase activity might be activated as a result of chromosomal translocations or point mutations, interference with this activity might reverse the cellular phenotype whether it is hypo- or hyperplastic. Alternatively, in cases in which cellular CBP activity is reduced as a result of haploinsufficiency or inactivating mutations, a compound that stimulates acetyltransferase activity of the remaining allele or that of p300 might allow for compensation of the defect. Treatment of any disorder caused by defects involving the CBP and p300 genes or CBP- and p300-regulated transcription factors rests entirely on a thorough understanding of the molecular and cellular environment in which CBP and p300 function.

An example for the successful manipulation of the acetylation balance in the cell comes from studies that use the drug trichostatin A. Trichostatin A, which is a deacetylase inhibitor, has been successfully used to activate silenced transgenes in the context of gene delivery vectors designed for use in gene therapy.165 Furthermore, drugs targeting histone deacetylases have been used against malaria and toxoplasmosis.166 Thus, a detailed understanding of the role of protein acetylation might reveal new approaches to controlling gene expression and treating human diseases.


    Acknowledgments

I want to thank Margaret Chou, Merlin Crossley, Richard Eckner, Stuart Orkin, Morty Poncz, and Mitchell Weiss for helpful suggestions and critical reading of the manuscript. Naturally, the survey of a burgeoning field such as this might not do justice to all contributions. Therefore, I apologize to those whose work is not represented here.


    Footnotes

Submitted April 21, 1999; accepted September 30, 1999.

Reprints: Gerd A. Blobel, MD, PhD, Abramson Pediatric Research Center #316, Children's Hospital of Philadelphia, 34th St and Civic Center Blvd, Philadelphia, PA 19104.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.


    References
Top
Introduction
Overview
Roles of CBP and...
CBP and p300 in...
Mechanisms of CBP and...
Summary and perspective
References

1. Sieweke MH, Graf T. A transcription factor party during blood cell differentiation. Curr Opin Genet Dev. 1998;8:545-551[Medline] [Order article via Infotrieve].

2. Shivdasani RA, Orkin SH. The transcriptional control of hematopoiesis. Blood. 1996;87:4025-4039[Free Full Text].

3. Petrij F, Giles RH, Dauwerse HG, et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature (London). 1995;376:348-351[Medline] [Order article via Infotrieve].

4. Tanaka Y, Naruse I, Maekawa T, Masuya H, Shiroishi T, Ishii S. Abnormal skeletal patterning in embryos lacking a single Cbp allele: a partial similarity with Rubinstein-Taybi. Proc Natl Acad Sci USA. 1997;94:10,215-10,220[Abstract/Free Full Text].

5. Kung AL, Rebel VI, Bronson RT, Ch'ng LE, Sieff CA, Livingston DM, Yao T-P. Gene dose-dependent control of hematopoietic differentiation and hematologic tumor suppression by CBP. Submitted 1999.

6. Oike Y, Takakura N, Hata A, et al. Mice homozygous for a truncated form of CREB-binding protein exhibit defects in hematopoiesis and vasculo-angiogenesis. Blood. 1999;93:2771-2779[Abstract/Free Full Text].

7. Eckner R. p300 and CBP as transcriptional regulators and targets of oncogenic events. Biol Chem. 1996;377:685-688.

8. Shikama N, Lyon J, LaThangue NB. The p300/CBP family: integrating signals with transcription factors and chromatin. Trends Cell Biol. 1997;7:230-236.

9. Giles RH, Peters DJM, Breuning MH. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet. 1998;14:178-183[Medline] [Order article via Infotrieve].

10. Chrivia JC, Kwok RPS, Lamb N, Hagiwara M, Montminy MR, Goodman RG. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature (London). 1993;365:855-859[Medline] [Order article via Infotrieve].

11. Eckner R, Ewen ME, Newsome D, et al. Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kd protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev. 1994;8:869-884[Abstract/Free Full Text].

12. Kawasaki H, Eckner R, Yao T, et al. Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature. 1998;393:284-289[Medline] [Order article via Infotrieve].

13. Yao T-P, Oh SP, Fuchs M, et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell. 1998;93:361-372[Medline] [Order article via Infotrieve].

14. Shi Y, Mello C. A CBP/p300 homolog specifies multiple differentiation pathways in Caennorhabditis elegans. Genes Dev. 1997;12:943-955[Abstract/Free Full Text].

15. Kamei Y, Xu L, Heinzel T, et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell. 1996;85:403-414[Medline] [Order article via Infotrieve].

16. Horvai AE, Xu L, Korzus E, et al. Nuclear integration of JAK/STAT and RAS/ AP-1 signaling by CBP and p300. Proc Natl Acad Sci U S A. 1997;94:1074-1079[Abstract/Free Full Text].

17. Akimaru H, Chen Y, Dai P, et al. Drosophila CBP is a co-activator of cubitus interruptus in hedgehog signalling. Nature (London). 1997;386:735-738[Medline] [Order article via Infotrieve].

18. Akimaru H, Hou D-X, Ishii S. Drosophila CBP is required for dorsal-dependent twist expression. Nature (London). 1997;17:211-214.

19. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell. 1997;89:1175-1184[Medline] [Order article via Infotrieve].

20. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM. Binding and modulation of p53 by p300/CBP coactivators. Nature (London). 1997;387:823-827[Medline] [Order article via Infotrieve].

21. Gu W, Shi X-L, Roeder RG. Synergistic activation of transcription by CBP and p53. Nature (London). 1997;387:819-823[Medline] [Order article via Infotrieve].

22. Lee KC, Crowe AJ, Barton MC. p53-mediated repression of alpha-fetoprotein gene expression by specific DNA binding. Mol Cell Biol. 1999;19:1279-1288[Abstract/Free Full Text].

23. Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature (London). 1996;384:641-643[Medline] [Order article via Infotrieve].

24. Ogryzko VV, Schiltz LR, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 1996;87:953-959[Medline] [Order article via Infotrieve].

25. Hebbes TR, Clayton AL, Thorne AW, Crane-Robinson C. Core histone hyperacetylation co-maps with generalized DNase I sensitivity in the chicken beta -globin chromosomal domain. EMBO J. 1994;13:1823-1830[Medline] [Order article via Infotrieve].

26. Pazin MJ, Kadonaga JT. What's up and down with histone deacetylation and transcription. Cell. 1997;89:325-328[Medline] [Order article via Infotrieve].

27. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 1997;90:595-606[Medline] [Order article via Infotrieve].

28. Sakaguchi K, Herrera JE, Saito S, et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 1998;12:2831-2841[Abstract/Free Full Text].

29. Liu L, Scolnick DM, Trievel RC, et al. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol. 1999;19:1202-1209[Abstract/Free Full Text].

30. Waltzer L, Bienz M. Drosophila CBP represses the transcription factor TCF to antagonize Wingless signalling. Nature (London). 1998;395:521-525[Medline] [Order article via Infotrieve].

31. Zhang W, Bieker JJ. Acetylation and modulation of erythroid Kruppel-like factor (EKLF) activity by interaction with histone acetyltransferases. Proc Natl Acad Sci U S A. 1998;95:9855-9860[Abstract/Free Full Text].

32. Boyes J, Byfield P, Nakatani Y, Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature. 1998;396:594-598[Medline] [Order article via Infotrieve].

33. Hung H-L, Lau J, Weiss MJ, Blobel GA. CREB-Binding Protein (CBP) acetylates hematopoietic transcription factor GATA-1 at functionally important sites. Mol Cell Biol. 1999;19:3496-3505[Abstract/Free Full Text].

34. Li Q, Herrler M, Landsberger N, et al. Xenopus NF-Y pre-sets chromatin to potentiate p300 and acetylation-responsive transcription from the Xenopus hsp70 promoter in vivo. EMBO J. 1998;17:6300-6315[Medline] [Order article via Infotrieve].

35. Imhof A, Yang XJ, Ogryzko VV, Nakatani Y, Wolfe AP, Ge H. Acetylation of general transcription factors by histone acetyltransferases. Current Biol. 1997;7:689-692[Medline] [Order article via Infotrieve].

36. Wong J, Patterton D, Imhof A, Guschin D, Shi Y-B, Wolffe AP. Distinct requirements for chromatin assembly in transcriptional repression by thyroid hormone receptor and histone deacetylase. EMBO J. 1998;17:520-534[Medline] [Order article via Infotrieve].

37. Munshi N, Merika M, Yie J, Senger K, Chen G, Thanos D. Acetylation of HMG I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome. Mol Cell. 1998;2:457-467[Medline] [Order article via Infotrieve].

38. Moran E. DNA tumor transforming proteins and the cell cycle. Curr Opin Genet Dev. 1993;

39. Bayley ST, Mymryk JS. Adenovirus E1A proteins and transformation. Int J Oncol. 1994;5:425-444.

40. Weston K. The myb genes. Sem Cancer Biol. 1990;1:371-382[Medline] [Order article via Infotrieve].

41. Clarke MF, Kukowska-Latallo JF, Westin E, Smith M, Prochownik E. Constitutive expression of a c-myb cDNA blocks Friend murine erythroleukemia cell differentiation. Mol Cel. Biol. 1988;8:884-892[Abstract/Free Full Text].

42. McMahon J, Howe KM, Watson RJ. The induction of Friend erythroleukemia differentiation is markedly affected by expression of a transfected c-myb cDNA. Oncogene. 1988;3:717-720[Medline] [Order article via Infotrieve].

43. Todokoro K, Watson RJ, Higo H, et al. Down-regulation of c-myb gene expression is a prerequisite for erythropoietin-induced erythroid differentiation. Proc Natl Acad Sci U S A. 1988;21:267-272.

44. McClinton D, Stafford J, Brents L, Bender TP, Kuehl WM. Differentiation of mouse erythroleukemia cells is blocked by late up-regulation of a c-myb transgene. Mol Cell Biol. 1990;10:705-710[Abstract/Free Full Text].

45. Yanagisawa H, Nagasawa T, Kuramochi S, Abe T, Ikawa Y, Todokoro K. Constitutuive expression of exogenous c-myb gene causes maturation block in monocyte-macrophage differentiation. Biochim Biophys Acta. 1991;1088:380-384[Medline] [Order article via Infotrieve].

46. Weber BL, Westin EH, Clarke MF. Differentiation of mouse erythroleukemia cells is enhanced by alternatively spliced c-myb mRNA. Science. 1990;249:1291-1293[Abstract/Free Full Text].

47. Gewirtz AM, Calabretta B. A c-myb antisense oligonucleatide inhibits normal human hematopoiesis in vitro. Science. 1988;242:1303-1306[Abstract/Free Full Text].

48. Gewirtz AM, Anfossi G, Venturelli D, Valpreda S, Sims R, Calabretta B. G1/S transition in normal human T-lymphocytes requires the nuclear protein encoded by c-myb. Science. 1989;245:180-183[Abstract/Free Full Text].

49. Anfossi G, Gewirtz AM, Calabretta B. An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc Natl Acad Sci U S A.1989;86.

50. Mucenski ML, McLain K, Kier AB, et al. A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell. 1991;65:677-689[Medline] [Order article via Infotrieve].

51. Dai P, Akimaru H, Tanaka Y, et al. CBP as a transcriptional coactivator of c-Myb. Genes Dev. 1995;10:528-540[Abstract/Free Full Text].

52. Oelgeschläger M, Janknecht R, Krieg J, Schreek S, Lüscher B. Interaction of the co-activator CBP with Myb proteins: effects on Myb-specific transactivation and on the cooperativity with NF-M. EMBO J. 1996;15:2771-2780[Medline] [Order article via Infotrieve].

53. Hen R, Borrelli E, Chambon P. Repression of the immunoglobulin heavy chain enhancer by the adenovirus-2 E1A products. Science. 1985;230:1391-1394[Abstract/Free Full Text].

54. Bergman Y, Shavit D. Regulation of the Ig Kappa-chain enhancer by the adenovirus E1A gene products. Repression in lymphoid cells, activation in fibroblasts. J Immunol. 1988;140:2073-2080[Abstract/Free Full Text].

55. Shen C-P, Kadesch T. B-cell-specific transcription by an E47 homodimer. Mol Cell Biol. 1995;15:4518-4524[Abstract].

56. Bain G, Maandag ECR, Izon DJ, et al. E2A proteins are required for proper B cell development and initiation of immunoglobulin rearrangements. Cell. 1994;79:885-892[Medline] [Order article via Infotrieve].

57. Zhuang Y, Soriano P, Weintraub H. The helix-loop-helix gene E2A is required for B cell formation. Cell. 1994;79:875-884[Medline] [Order article via Infotrieve].

58. Zhuang Y, Kim C, Bartelmez S, Cheng P-F, Groudine M, Weintraub H. Helix-loop-helix transcription factors E12 and E47 are not essential for skeletal or cardiac myogenesis, erythropoiesis, chondrogenesis, or neurogenesis. Proc Natl Acad Sci U S A. 1992;89:12,132-12,136[Abstract/Free Full Text].

59. Eckner R, Yao T-P, Oldread E, Livingston DM. Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation. Genes Dev. 1996;10:2478-2490[Abstract/Free Full Text].

60. Pevny L, Simon MC, Robertson E, et al. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature (London). 1991;349:257-260[Medline] [Order article via Infotrieve].

61. Pevny L, Lin CS, D'Agati V, Simon MC, Orkin SH, Costantini F. Development of hematopoietic cells lacking transcription factor GATA-1. Development. 1995;121:163-172[Abstract].

62. Weiss MJ, Keller G, Orkin SH. Novel insights into erythroid development revealed through in vitro differentiation of GATA-1_ embryonic stem cells. Genes Dev. 1994;8:1184-1197[Abstract/Free Full Text].

63. Fujiwara Y, Browne CP, Cunniff K, Goff SC, Orkin SH. Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. Proc Natl Acad Sci U S A. 1996;93:12,355-12,358[Abstract/Free Full Text].

64. Weiss MJ, Orkin SH. Transcription factor GATA-1 permits survival and maturation of erythroid precursors by preventing apoptosis. Proc Natl Acad Sci U S A. 1995;92:9623-9627[Abstract/Free Full Text].

65. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J. 1997;16:3965-3973[Medline] [Order article via Infotrieve].

66. Weiss MJ, Yu C, Orkin SH. Erythroid-cell-specific properities of transcription factor GATA-1 revealed by phenotypic rescue of a gene targeted cell line. Mol Cell Biol. 1997;17:1642-1651[Abstract].

67. Higgs DR. Do LCRs open chromatin domains? Cell. 1998;95:299-302[Medline] [Order article via Infotrieve].

68. Blobel GA, Nakajima T, Eckner R, Montminy M, Orkin SH. CREB-bining protein (CBP) cooperates with transcription factor GATA-1 and is required for erythroid differentiation. Proc Natl Acad Sci U S A. 1998;95:2061-2066[Abstract/Free Full Text].

69. Sposi NM, Zon LI, Care A, et al. Cell cycle-dependent initiation and lineage-dependent abrogation of GATA-1 expression in pure differentiating hematopoietic progenitors. Proc Natl Acad Sci U S A. 1992;89:6353-6357[Abstract/Free Full Text].

70. Leonard M, Brice M, Engel JD, Papayannopoulou T. Dynamics of GATA transcription factor expression during erythroid differentiation. Blood. 1993;82:1071-1079[Abstract/Free Full Text].

71. Tsai F-Y, Keller G, Kuo FC, et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature (London). 1994;371:221-226[Medline] [Order article via Infotrieve].

72. Forsberg EC, Johnson K, Zaboikina TN, Mosser EA, Bresnick EH. Requirement of an E1A-sensitive coactivator for long-range transactivation by the beta -globin locus control region. J Biol Chem. 1999;274:26,850-26,859[Abstract/Free Full Text].

73. Andrews N, Erdjument-Bromage H, Davidson M, Tempst P, Orkin SH. Erythroid transcription factor NF-E2 is a hematopoietic-specific basic-leucine zipper protein. Nature (London). 1993;362:722-728[Medline] [Order article via Infotrieve].

74. Andrews NC, Kotkow KJ, Ney PA, Erdjument-Bromage H, Tempst P, Orkin SH. The ubiquitous subunit of erythroid transcription factor NF-E2 is a small basic-leucine zipper protein related to the v-maf oncogene. Proc Natl Acad Sci U S A. 1993;90:11,488-11,492[Abstract/Free Full Text].

75. Igarashi K, Kataoka K, Itoh K, Hayashi N, Nishizawa M, Yamamoto M. Regulation of transcription by dimerization of erythroid factor NF-E2 p45 with small Maf proteins. Nature (London). 1994;367:568-572[Medline] [Order article via Infotrieve].

76. Blank V, Andrews NC. The maf transcription factors: regulators of differentiation. Trends Biochem Sci. 1997;22:437-441[Medline] [Order article via Infotrieve].

77. Kobayashi A, Ito E, Toki T, et al. Molecular cloning and functional characterization of a new Cap'n' Collar family transcription factor Nrf3. J Biol Chem. 1999;274:6443-6452[Abstract/Free Full Text].

78. Shivdasani RA, Rosenblatt MF, Zucker-Franklin DC, et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoieitin/MGDF in megakaryocyte development. Cell. 1995;81:695-701[Medline] [Order article via Infotrieve].

79. Shivdasani RA, Orkin SH. Erythropoiesis and globin gene expression in mice lacking the transcription factor NF-E2. Proc Natl Acad Sci U S A. 1995;92.

80. Cheng X, Reginato MJ, Andrews NC, Lazar MA. The Transcriptional Integrator CREB- binding protein mediates positive cross talk between nuclear hormone receptors and the hematopoietic bZip protein p45/NF-E2. Mol Cell Biol. 1997;1:1407-1416.

81. Braverman LE, Utiger RD. The Thyroid: a Fundamental and Clinical Text. 6th ed. Philadelphia, PA: JB Lippincott; 1991.

82. Armstrong JA, Emerson BM. NF-E2 disrupts chromatin structure at human beta -globin locus control region hypersensitive site 2 in vitro. Mol Cell Biol. 1996;16:5634-5644[Abstract].

83. Miller IJ, Bieker JJ. A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Krüppel family of nuclear proteins. Mol Cell Biol. 1993;13:2776-2786[Abstract/Free Full Text].

84. Perkins AC, Sharpe AH, Orkin SH. Lethal beta -thalassaemia in mice lacking the erythroid CACCC-transcription factor EKLF. Nature (London). 1995;375:318-322[Medline] [Order article via Infotrieve].

85. Nuez B, Michalovich D, Bygrave A, Ploemacher R, Grosveld F. Defective haematopoiesis in fetal liver resulting from inactivation of the EKLF gene. Nature (London). 1995;375:316-318[Medline] [Order article via Infotrieve].

86. Perkins AC, Gaensler KM, Orkin SH. Silencing of human fetal globin expression is impaired in the absence of the adult beta-globin gene activator protein EKLF. Proc Natl Acad Sci U S A. 1996;93:12,267-12,271[Abstract/Free Full Text].

87. Wijgerde M, Gribnau J, Trimborn T, et al. The role of EKLF in human beta ---globin gene competition. Genes Dev. 1996;10:2894-2902[Abstract/Free Full Text].

88. Merika M, Orkin SH. Functional synergy and physical interactions of the erythroid transcription factor GATA-1 with Krüppel family proteins Sp1 and EKLF. Mol Cell Biol. 1995;15:2437-2447[Abstract].

89. Lekstrom-Himes J, Xanthopoulos KG. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J Biol Chem. 1998;273:28,545-28,548[Abstract/Free Full Text].

90. Yamanaka R, Lekstrom-Himes J, Barlow C, Wynshaw-Boris A, Xanthopoulos KG. CCAAT/enhancer binding proteins are critical components of the transcriptional regulation of hematopoiesis. Int J Mol Med. 1998;1:213-221[Medline] [Order article via Infotrieve].

91. Yamanaka R, Barlow C, Lekstrom-Himes J, et al. Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice. Proc Natl Acad Sci U S A. 1997;94:13,187[Abstract/Free Full Text].

92. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci U S A. 1997;94:569-574[Abstract/Free Full Text].

93. Screpanti I, Romani L, Musiani P, et al. Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J. 1995;14:1932-1941[Medline] [Order article via Infotrieve].

94. Tanaka T, Akira S, Yoshida K, et al. Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell. 1995;80:353-361[Medline] [Order article via Infotrieve].

95. Poli V. The role of C/EBP isoforms in the control of inflammatory and native immunity functions. J Biol Chem. 1998;45:29,279-29,282.

96. Mink S, Haenig B, Klempnauer KH. Interaction and functional collaboration of p300 and C/EBPbeta . Mol Cell Biol. 1997;17:6609-6617[Abstract].

97. Wasylyk B, Hahn SL, Giovane A. The Ets family of transcription factors. Eur J Biochem. 1993;211:7-18[Medline] [Order article via Infotrieve].

98. Metz T, Graf T. v-myb and v-ets transform chicken erythroid cells and cooperate in trans and in cis to induce distinct differentiation phenotypes. Genes Dev. 1991;5:369-380[Abstract/Free Full Text].

99. Metz T, Graf T. Fusion of the nuclear oncoproteins v-Myb and v-Ets is required for the leukemogenicity of E26 virus. Cell. 1991;66:95-105[Medline] [Order article via Infotrieve].

100. Bories J-C, Willerford DM, Grevin D, et al. Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene. Nature (London). 1995;377:635-638[Medline] [Order article via Infotrieve].

101. Muthusamy N, Barton K, Leiden JM. Defective activation and survival of T cells lacking the Ets-1 transcription factor. Nature (London). 1995;377:639-642[Medline] [Order article via Infotrieve].

102. Wasylyk B, Wasylyk C, Flores P, Begue A, Leprince D, Stehelin D. The c-ets proto-oncogenes encode transcription factors that cooperate with c-Fos and c-Jun for transcriptional activation. Nature (London). 1990;346:191-193[Medline] [Order article via Infotrieve].

103. Dudek H, Tantravahi RV, Rao VN, Reddy ES, Reddy EP. Myb and Ets proteins cooperate in transcriptional activation of the mim-1 promoter. Proc Natl Acad Sci U S A. 1992;89:1291-1295[Abstract/Free Full Text].

104. Sharpiro LH. Myb and Ets proteins cooperate to transactivate an early myeloid gene. J Biol Chem. 1995;270:8763-8771[Abstract/Free Full Text].

105. Postigo AA, Sheppard AM, Mucenski ML, Dean DC. c-Myb and Ets proteins synergize to overcome transcriptional repression by ZEB. EMBO J. 1997;16:3924-3934[Medline] [Order article via Infotrieve].

106. Ratajczak MZ, Perrotti D, Melotti P, et al. Myb and Ets proteins are candidate regulators of c-kit expression in human hematopoietic cells. Blood. 1998;91:1934-1946[Abstract/Free Full Text].

107. Lemarchandel V, Ghysdael J, Mignotte V, Rahuel C, Romeo PH. GATA and ETS cis-acting sequences mediate megakaryocyte-specific gene expression. Mol Cell Biol. 1993;13:668-676[Abstract/Free Full Text].

108. Bastian LS, Yagi M, Chan C, Roth GJ. Analysis of the megakaryocyte glycoprotein IX promoter identifies positive and negative regulatory domains and functional GATA and Ets sites. J Biochem. 1996;271:18,554-18,560.

109. Hashimoto Y, Ware J. Identification of essential GATA and Ets binding motifs within the promoter of the platelet glycopretein Ib alpha gene. J Biochem. 1995;270:24,532-24,539.

110. Deveaux S, Filipe A, Lemarchandel V, Ghysdael J, Romeo PH, Mignotte V. Analysis of the thrombopoietin receptor (MPL) promoter implicates GATA and Ets proteins in the coregulation of megakaryocyte-specific genes. Blood. 1996;87:4678-4685[Abstract/Free Full Text].

111. Minami T, Tachibana K, Imanishi T, Doi T. Both Ets-1 and GATA-1 are essential for positive regulation of platelet factor 4 gene expression. Eur J Biochem. 1998;258:879-889[Medline] [Order article via Infotrieve].

112. Yang C, Shapiro LH, Rivera M, Kumar A, Brindle PK. A role for CREB binding protein and p300 transcriptional coactivators in Ets-1 transactivation functions. Mol Cell Biol. 1998;18:2218-2229[Abstract/Free Full Text].

113. Yamamoto H, Kihara-Negishi F, Yamada T, Hashimoto Y, Oikawa T. Physical and functional interactions between the transcription factor PU.1 and the coactivator CBP. Oncogene. 1999;18:1495-1501[Medline] [Order article via Infotrieve].

114. Hromas R, Orazi A, Neiman RS, et al. Hematopoietic lineage- and stage-restricted expression of the ETS oncogene family member PU.1. Blood. 1993;82:2998-3004[Abstract/Free Full Text].

115. Kitabayashi I, Yokoyama A, Shimizu K, Ohki M. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J. 1998;17:2994-3004[Medline] [Order article via Infotrieve].

116. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278:1059-1064[Abstract/Free Full Text].

117. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84:321-330[Medline] [Order article via Infotrieve].

118. Sasaki K, Yagi H, Bronson RT, et al. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta. Proc Natl Acad Sci U S A. 1996;93:12,359-12,363[Abstract/Free Full Text].

119. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A. 1996;93:3444-3449[Abstract/Free Full Text].

120. Wang Q, Stacy T, Miller JD, et al. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell. 1996;87:697-708[Medline] [Order article via Infotrieve].

121. Niki M, Okada H, Takano H, et al. Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor. Proc Natl Acad Sci U S A. 1997;94:5697-5702[Abstract/Free Full Text].

122. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A. 1998;95:10,860-10,865[Abstract/Free Full Text].

123. Lutterbach B, Westendorf JJ, Linggi B, et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol. 1998;18:7176-7184[Abstract/Free Full Text].

124. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol. 1998;18:7185-7191[Abstract/Free Full Text].

125. Hernandez-Munain C, Krangel MS. Regulation of the T-cell receptor delta enhancer by functional cooperation between c-Myb and core-binding factors. Mol Cell Biol. 1994;14:473-483[Abstract/Free Full Text].

126. Britos-Bray M, Friedman AD. Core binding factor cannot synergistically activate the myeloperoxidase proximal enhancer in immature myeloid cells without c-Myb. Mol Cell Biol. 1997;17:5127-5135[Abstract].

127. Zhang DE, Hetherington CJ, Meyers S, et al. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol. 1996;16:1231-1240[Abstract].

128. Hernandez-Munain C, Krangel MS. c-Myb and core-binding factor/PEBP2 display functional synergy but bind independently to adjacent sites in the T-cell receptor delta enhancer. Mol Cell Biol. 1995;15:3090-3099[Abstract].

129. Rubinstein JH, Taybi H. Broad thumbs and toes and facial abnormalities: a possible mental retardation syndrome. Am J Dis Child. 1963;105:588-608.

130. Miller RW, Rubinstein JH. Tumors in Rubinstein-Taybi syndrome. Am J Med Gen. 1995;56:112-115[Medline] [Order article via Infotrieve].

131. Borrow J, Stanton VPJ, Andresen JM, et al. The translocation t(8;16)(p11;13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nature Genet. 1996;14:33-41[Medline] [Order article via Infotrieve].

132. Giles RH, Dauwerse JG, Higgins C, et al. Detection of CBP rearrangements in acute myelogenous leukemia with t(8;16). Leukemia. 1997;11:2087-2096[Medline] [Order article via Infotrieve].

133. He LZ, Guidez F, Tribioli C, et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nature Genet. 1998;18:126-135[Medline] [Order article via Infotrieve].

134. Grignani F, De Matteis S, Nervi C, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (London). 1998;391:815-818[Medline] [Order article via Infotrieve].

135. Lin RJ, Nagy L, Inoue S, Shao W, Miller WHJ, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (London). 1998;391:811-814[Medline] [Order article via Infotrieve].

136. Taki T, Sako M, Tsuchida M, Hayashi Y. The t(11;16)(q2313.3) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood. 1997;89:3945-3950[Abstract/Free Full Text].

137. Sobulo OM, Borrow J, Tomek R, et al. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci U S A. 1997;94:8732-8737[Abstract/Free Full Text].

138. Rowley JD, Reshmi S, Sobulo O, et al. All patients with the T(11;16) (q23; p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood. 1997;90:535-541[Abstract/Free Full Text].

139. Satake N, Ishida Y, Otoh Y, et al. Novel MLL-CBP fusion transcript in therapy-related chronic myelomonocytic leukemia with a t(11;16)(q23;p13) chromosome translocation. Genes: Chromosomes Cancer.; 1997:20:60-63.

140. Ida K, Kitabayashi I, Taki T, et al. Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11,22)(q23;q13). Blood. 1997;90:4699-4704[Abstract/Free Full Text].

141. Djabali M, Selleri L, Parry P, Bower M, Young BD, Evans GA. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nature Genet. 1992;2:113-118[Medline] [Order article via Infotrieve].

142. Gu Y, Nakamura T, Alder H, et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell. 1992;71:701-708[Medline] [Order article via Infotrieve].

143. Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell. 1992;71:691-700[Medline] [Order article via Infotrieve].

144. Carey M. The enhanceosome and transcriptional synergy. Cell. 1998;92:5-8[Medline] [Order article via Infotrieve].

145. Yang X-J, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature (London). 1996;382:319-324[Medline] [Order article via Infotrieve].

146. Chen H, Lin RJ, Schiltz RL, et al. Nuclear receptor Coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell. 1997;90:569-580[Medline] [Order article via Infotrieve].

147. Spencer TE, Jenster G, Burcin MM, et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature (London). 1997;389:194-198[Medline] [Order article via Infotrieve].

148. Chang T-J, Scher BM, Waxman S, Scher W. Inhibition of mouse GATA-1 function by the glucocorticoid receptor: possible mechanism of steroid inhibition of erythroleukemia cell differentiation. Mol Endocrinol. 1993;7:528-542[Abstract/Free Full Text].

149. Blobel GA, Sieff CA, Orkin SH. Ligand-dependent repression of the erythroid transcription factor GATA-1 by the estrogen receptor. Mol Cell Biol. 1995;15:3147-3153[Abstract].

150. Blobel GA, Orkin SH. Estrogen-induced apoptosis by inhibition of the erythroid transcription factor GATA-1. Mol Cell Biol. 1996;16:1687-1694[Abstract].

151. Kwok RP, Lunblad JR, Chrivia JC, et al. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature (London). 1994;370:223-226[Medline] [Order article via Infotrieve].

152. Abraham SE, Lobo S, Yaciuk P, Wang HG, Moran E. p300, and p300-associated proteins, are components of TATA-binding protein (TBP) complexes. Oncogene. 1993;8:1639-1647[Medline] [Order article via Infotrieve].

153. Swope DL, Mueller CL, Chrivia JC. CREB-binding protein activates transcription through multiple domains. J Biol Chem. 1996;271:28,138-28,145[Abstract/Free Full Text].

154. Dallas PB, Yaciuk P, Moran E. Characterization of monoclonal antibodies raised against p300: both p300 and CBP are present in intracellular TBP complexes. J Virol. 1997;71:1726-1731[Abstract].

155. Sang N, Avantaggiati ML, Giordano A. Roles of p300, pocket proteins, and hTBP in E1A-mediated transcriptional regulation and inhibition of p53 transactivation activity. J Cell Biochem. 1997;66:277-285[Medline] [Order article via Infotrieve].

156. Kee B, Arias J, Montminy M. Adaptor mediated recruitment of RNA polymerase II to a signal dependent activator. J Biol Chem. 1996;271:2373-2375[Abstract/Free Full Text].

157. Nakajima T, Uchida C, Anderson SF, Parvin JD, Montminy M. Analysis of a cAMP-responsive activator reveals a two-component mechanism for transcriptional induction via signal-dependent factors. Genes Dev. 1997;11:738-747[Abstract/Free Full Text].

158. Nakajima T, Uchida C, Anderson SF, et al. RNA helicase A mediates association of CBP with RNA polymerase II. Cell. 1997;90:1107-1112[Medline] [Order article via Infotrieve].

159. Cho H, Orphanides G, Sun X, et al. A human RNA polymerase II complex containing factors that modify chromatin structure. Mol Cell Biol. 1998;18:5355-5363[Abstract/Free Full Text].

160. Neish AS, Anderson SF, Schlegel BP, Wei W, Parvin JD. Factors associated with the mammalian RNA polymerase II holoenzyme. Nucleic Acids Res. 1998;26:847-853[Abstract/Free Full Text].

161. Korzus E, Torchia J, Rose DW, et al. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science. 1998;279:703-707[Abstract/Free Full Text].

162. Boyes J, Omichinsky J, Clark D, Pikaart M, Felsenfeld G. Perturbation of nucleosome structure by the erythroid transcription factor GATA-1. J Mol Biol. 1998;279:529-544[Medline] [Order article via Infotrieve].

163. Kadonaga JT. Eukaryotic transcription: an interlaced network of transcription factors and chromatin-modifying machines. Cell. 1998;92:307-313[Medline] [Order article via Infotrieve].

164. Armstrong JA, Bieker JJ, Emerson BM. A SWI/SNF-related chromatin remodeling complex, E-RC1, is required for tissue-specific transcriptional regulation by EKLF in vitro. Cell. 1998;95:93-104[Medline] [Order article via Infotrieve].

165. Chen WY, Bailey EC, McCune SL, Dong J-Y, Townes TM. Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc Natl Acad Sci U S A. 1997;94:5798-5803[Abstract/Free Full Text].

166. Darkin-Rattray SJ, Gurnett AM, Myers RW, et al. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc Natl Acad Sci U S A. 1996;93:13,143-13,147[Abstract/Free Full Text].

167. Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou M-M. Structure and ligand of a histone acetyltransferase bromodomain. Nature (London). 1999;399:491-496[Medline] [Order article via Infotrieve].

© 2000 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
Y. Chen, P. Haviernik, K. D. Bunting, and Y.-C. Yang
Cited2 is required for normal hematopoiesis in the murine fetal liver
Blood, October 15, 2007; 110(8): 2889 - 2898.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Forster, S. Gallinat, J. Jablonska, S. Weiss, H.-P. Elsasser, and W. Lutz
p300 Protein Acetyltransferase Activity Suppresses Systemic Lupus Erythematosus-Like Autoimmune Disease in Mice
J. Immunol., June 1, 2007; 178(11): 6941 - 6948.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Shimizu, C. D. Trainor, K. Nishikawa, M. Kobayashi, K. Ohneda, and M. Yamamoto
GATA-1 Self-association Controls Erythroid Development in Vivo
J. Biol. Chem., May 25, 2007; 282(21): 15862 - 15871.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
A. Kim, H. Zhao, I. Ifrim, and A. Dean
{beta}-Globin Intergenic Transcription and Histone Acetylation Dependent on an Enhancer
Mol. Cell. Biol., April 15, 2007; 27(8): 2980 - 2986.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M.-C. Chiang, H.-M. Chen, Y.-H. Lee, H.-H. Chang, Y.-C. Wu, B.-W. Soong, C.-M. Chen, Y.-R. Wu, C.-S. Liu, D.-M. Niu, et al.
Dysregulation of C/EBP{alpha} by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease
Hum. Mol. Genet., March 1, 2007; 16(5): 483 - 498.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. W. Georgantas III, R. Hildreth, S. Morisot, J. Alder, C.-g. Liu, S. Heimfeld, G. A. Calin, C. M. Croce, and C. I. Civin
CD34+ hematopoietic stem-progenitor cell microRNA expression and function: A circuit diagram of differentiation control
PNAS, February 20, 2007; 104(8): 2750 - 2755.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. Y. Kim, E. M. Woo, Y. T. E. Chong, D. R. Homenko, and W. L. Kraus
Acetylation of Estrogen Receptor {alpha} by p300 at Lysines 266 and 268 Enhances the Deoxyribonucleic Acid Binding and Transactivation Activities of the Receptor
Mol. Endocrinol., July 1, 2006; 20(7): 1479 - 1493.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
O. H. Kramer, D. Baus, S. K. Knauer, S. Stein, E. Jager, R. H. Stauber, M. Grez, E. Pfitzner, and T. Heinzel
Acetylation of Stat1 modulates NF-{kappa}B activity.
Genes & Dev., February 15, 2006; 20(4): 473 - 485.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. N. Bhalla
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
J. Clin. Oncol., June 10, 2005; 23(17): 3971 - 3993.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Q. Zhang, H. Y. Wang, M. Marzec, P. N. Raghunath, T. Nagasawa, and M. A. Wasik
STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes
PNAS, May 10, 2005; 102(19): 6948 - 6953.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Liu, T. Shen, L. Huynh, M. I. Klisovic, L. J. Rush, J. L. Ford, J. Yu, B. Becknell, Y. Li, C. Liu, et al.
Interplay of RUNX1/MTG8 and DNA Methyltransferase 1 in Acute Myeloid Leukemia
Cancer Res., February 15, 2005; 65(4): 1277 - 1284.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
K. B. Kindle, P. J. F. Troke, H. M. Collins, S. Matsuda, D. Bossi, C. Bellodi, E. Kalkhoven, P. Salomoni, P. G. Pelicci, S. Minucci, et al.
MOZ-TIF2 Inhibits Transcription by Nuclear Receptors and p53 by Impairment of CBP Function
Mol. Cell. Biol., February 1, 2005; 25(3): 988 - 1002.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
H. Zhao and A. Dean
An insulator blocks spreading of histone acetylation and interferes with RNA polymerase II transfer between an enhancer and gene
Nucleic Acids Res., September 15, 2004; 32(16): 4903 - 4919.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. Takeshita, K. Suzuki, S. Sasaki, N. Ishii, D. M. Klinman, and K. J. Ishii
Transcriptional Regulation of the Human TLR9 Gene
J. Immunol., August 15, 2004; 173(4): 2552 - 2561.
[Abstract] [Full Text] [PDF]

Home page
 Eukaryot CellHome page
P. J. Rooney and B. S. Klein
Sequence Elements Necessary for Transcriptional Activation of BAD1 in the Yeast Phase of Blastomyces dermatitidis
Eukaryot. Cell, June 1, 2004; 3(3): 785 - 794.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. K. Hwang, C. S. Kim, H. S. Choi, S. R. McKercher, and H. H. Loh
Transcriptional Regulation of Mouse {micro} Opioid Receptor Gene by PU.1
J. Biol. Chem., May 7, 2004; 279(19): 19764 - 19774.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
S. Aittomaki, J. Yang, E. W. Scott, M. C. Simon, and O. Silvennoinen
Molecular basis of Stat1 and PU.1 cooperation in cytokine-induced Fc{gamma} receptor I promoter activation
Int. Immunol., February 1, 2004; 16(2): 265 - 274.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. J. Dempsey, L. S. Ojalvo, D. W. Wu, and J. A. Little
Induction of an embryonic globin gene promoter by short-chain fatty acids
Blood, December 1, 2003; 102(12): 4214 - 4222.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
K. J. McManus and M. J. Hendzel
Quantitative Analysis of CBP- and P300-Induced Histone Acetylations In Vivo Using Native Chromatin
Mol. Cell. Biol., November 1, 2003; 23(21): 7611 - 7627.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
Z. Deng, C.-J. Chen, M. Chamberlin, F. Lu, G. A. Blobel, D. Speicher, L. A. Cirillo, K. S. Zaret, and P. M. Lieberman
The CBP Bromodomain and Nucleosome Targeting Are Required for Zta-Directed Nucleosome Acetylation and Transcription Activation
Mol. Cell. Biol., April 15, 2003; 23(8): 2633 - 2644.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
Z. Zhang and C. T. Teng
Phosphorylation of Kruppel-like factor 5 (KLF5/IKLF) at the CBP interaction region enhances its transactivation function
Nucleic Acids Res., April 15, 2003; 31(8): 2196 - 2208.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
M. J. Walters, G. A. Wayman, J. C. Notis, R. H. Goodman, T. R. Soderling, and J. L. Christian
Calmodulin-dependent protein kinase IV mediated antagonism of BMP signaling regulates lineage and survival of hematopoietic progenitors
Development, March 5, 2003; 129(6): 1455 - 1466.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
E. Kalkhoven, J. H. Roelfsema, H. Teunissen, A. den Boer, Y. Ariyurek, A. Zantema, M. H. Breuning, R. C.M. Hennekam, and D. J.M. Peters
Loss of CBP acetyltransferase activity by PHD finger mutations in Rubinstein-Taybi syndrome
Hum. Mol. Genet., February 15, 2003; 12(4): 441 - 450.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
D. L. Letting, C. Rakowski, M. J. Weiss, and G. A. Blobel
Formation of a Tissue-Specific Histone Acetylation Pattern by the Hematopoietic Transcription Factor GATA-1
Mol. Cell. Biol., February 15, 2003; 23(4): 1334 - 1340.
[Abstract] [Full Text] [PDF]

Home page
 Recent Prog Horm ResHome page
B. Tian and A. R. Brasier
Identification of a Nuclear Factor Kappa B-dependent Gene Network
Recent Prog. Horm. Res., January 1, 2003; 58(1): 95 - 130.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. S. Bush, M. St. Coeur, K. K. Resendes, and A. G. Rosmarin
GA-binding protein (GABP) and Sp1 are required, along with retinoid receptors, to mediate retinoic acid responsiveness of CD18 (beta 2 leukocyte integrin): a novel mechanism of transcriptional regulation in myeloid cells
Blood, January 1, 2003; 101(1): 311 - 317.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. I. Rebel, A. L. Kung, E. A. Tanner, H. Yang, R. T. Bronson, and D. M. Livingston
Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal
PNAS, November 12, 2002; 99(23): 14789 - 14794.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
W. Hong, R. J. Resnick, C. Rakowski, D. Shalloway, S. J. Taylor, and G. A. Blobel
Physical and Functional Interaction Between the Transcriptional Cofactor CBP and the KH Domain Protein Sam68
Mol. Cancer Res., November 1, 2002; 1(1): 48 - 55.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Bandyopadhyay, N. A. Okan, E. Bales, L. Nascimento, P. A. Cole, and E. E. Medrano
Down-Regulation of p300/CBP Histone Acetyltransferase Activates a Senescence Checkpoint in Human Melanocytes
Cancer Res., November 1, 2002; 62(21): 6231 - 6239.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. M. Kiekhaefer, J. A. Grass, K. D. Johnson, M. E. Boyer, and E. H. Bresnick
Hematopoietic-specific activators establish an overlapping pattern of histone acetylation and methylation within a mammalian chromatin domain
PNAS, October 29, 2002; 99(22): 14309 - 14314.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Zor, B. M. Mayr, H. J. Dyson, M. R. Montminy, and P. E. Wright
Roles of Phosphorylation and Helix Propensity in the Binding of the KIX Domain of CREB-binding Protein by Constitutive (c-Myb) and Inducible (CREB) Activators
J. Biol. Chem., October 25, 2002; 277(44): 42241 - 42248.
[Abstract] [Full Text] [PDF]

Home page
 Microbiol. Mol. Biol. Rev.Home page
B. Albrecht and M. D. Lairmore
Critical Role of Human T-Lymphotropic Virus Type 1 Accessory Proteins in Viral Replication and Pathogenesis
Microbiol. Mol. Biol. Rev., September 1, 2002; 66(3): 396 - 406.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
C.-T. Yu, M.-H. L. Feng, H.-m. Shih, and M.-Z. Lai
Increased p300 Expression Inhibits Glucocorticoid Receptor-T-Cell Receptor Antagonism but Does Not Affect Thymocyte Positive Selection
Mol. Cell. Biol., July 1, 2002; 22(13): 4556 - 4566.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
W. Hong, A. Y. Kim, S. Ky, C. Rakowski, S.-B. Seo, D. Chakravarti, M. Atchison, and G. A. Blobel
Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1
Mol. Cell. Biol., June 1, 2002; 22(11): 3729 - 3743.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. A. Dames, M. Martinez-Yamout, R. N. De Guzman, H. J. Dyson, and P. E. Wright
From the Cover: Structural basis for Hif-1alpha /CBP recognition in the cellular hypoxic response
PNAS, April 16, 2002; 99(8): 5271 - 5276.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
E. Kalkhoven, H. Teunissen, A. Houweling, C. P. Verrijzer, and A. Zantema
The PHD Type Zinc Finger Is an Integral Part of the CBP Acetyltransferase Domain
Mol. Cell. Biol., April 1, 2002; 22(7): 1961 - 1970.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. Ray, C. T. Sherman, M. Lu, and A. R. Brasier
Angiotensinogen Gene Expression Is Dependent on Signal Transducer and Activator of Transcription 3-Mediated p300/cAMP Response Element Binding Protein-Binding Protein Coactivator Recruitment and Histone Acetyltransferase Activity
Mol. Endocrinol., April 1, 2002; 16(4): 824 - 836.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
K. D. Johnson, J. E. Norton, and E. H. Bresnick
Requirements for utilization of CREB binding protein by hypersensitive site two of the {beta}-globin locus control region
Nucleic Acids Res., April 1, 2002; 30(7): 1522 - 1530.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
G. A. Blobel
CBP and p300: versatile coregulators with important roles in hematopoietic gene expression
J. Leukoc. Biol., April 1, 2002; 71(4): 545 - 556.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. V. Emelyanov, C. R. Kovac, M. A. Sepulveda, and B. K. Birshtein
The Interaction of Pax5 (BSAP) with Daxx Can Result in Transcriptional Activation in B Cells
J. Biol. Chem., March 22, 2002; 277(13): 11156 - 11164.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Kumatori, D. Yang, S. Suzuki, and M. Nakamura
Cooperation of STAT-1 and IRF-1 in Interferon-gamma -induced Transcription of the gp91phox Gene
J. Biol. Chem., March 8, 2002; 277(11): 9103 - 9111.
[Abstract] [Full Text] [PDF]

Home page
 Cell Growth Differ.Home page
H. Yamamoto, F. Kihara-Negishi, T. Yamada, M. Suzuki, T. Nakano, and T. Oikawa
Interaction between the Hematopoietic Ets Transcription Factor Spi-B and the Coactivator CREB-binding Protein Associated with Negative Cross-talk with c-Myb
Cell Growth Differ., February 1, 2002; 13(2): 69 - 75.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
W. Zhang, J. W. Nisbet, B. Albrecht, W. Ding, F. Kashanchi, J. T. Bartoe, and M. D. Lairmore
Human T-Lymphotropic Virus Type 1 p30II Regulates Gene Transcription by Binding CREB Binding Protein/p300
J. Virol., October 15, 2001; 75(20): 9885 - 9895.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Ozawa, M. Towatari, S. Tsuzuki, F. Hayakawa, T. Maeda, Y. Miyata, M. Tanimoto, and H. Saito
Histone deacetylase 3 associates with and represses the transcription factor GATA-2
Blood, October 1, 2001; 98(7): 2116 - 2123.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. H. Broyles, V. Belegu, C. R. DeWitt, S. N. Shah, C. A. Stewart, Q. N. Pye, and R. A. Floyd
Specific repression of beta -globin promoter activity by nuclear ferritin
PNAS, July 31, 2001; 98(16): 9145 - 9150.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
E. T. Manning, T. Ikehara, T. Ito, J. T. Kadonaga, and W. L. Kraus
p300 Forms a Stable, Template-Committed Complex with Chromatin: Role for the Bromodomain
Mol. Cell. Biol., June 15, 2001; 21(12): 3876 - 3887.
[Abstract] [Full Text]

Home page
 Mol. Cell. Biol.Home page
Z. Duan, G. Stamatoyannopoulos, and Q. Li
Role of NF-Y in In Vivo Regulation of the {gamma}-Globin Gene
Mol. Cell. Biol., May 1, 2001; 21(9): 3083 - 3095.
[Abstract] [Full Text]

Home page
 Mol. Cell. Biol.Home page
W. Zhang, S. Kadam, B. M. Emerson, and J. J. Bieker
Site-Specific Acetylation by p300 or CREB Binding Protein Regulates Erythroid Kruppel-Like Factor Transcriptional Activity via Its Interaction with the SWI-SNF Complex
Mol. Cell. Biol., April 1, 2001; 21(7): 2413 - 2422.
[Abstract] [Full Text]

Home page
 Genes Dev.Home page
J. D. Crispino, M. B. Lodish, B. L. Thurberg, S. H. Litovsky, T. Collins, J. D. Molkentin, and S. H. Orkin
Proper coronary vascular development and heart morphogenesis depend on interaction of GATA-4 with FOG cofactors
Genes & Dev., April 1, 2001; 15(7): 839 - 844.
[Abstract] [Full Text]

Home page
 Mol. Cell. Biol.Home page
C.-Y. Gui and A. Dean
Acetylation of a Specific Promoter Nucleosome Accompanies Activation of the {varepsilon}-Globin Gene by {beta}-Globin Locus Control Region HS2
Mol. Cell. Biol., February 15, 2001; 21(4): 1155 - 1163.
[Abstract] [Full Text]

Home page
 Nucleic Acids ResHome page
L. Bordoli, M. Netsch, U. Luthi, W. Lutz, and R. Eckner
Plant orthologs of p300/CBP: conservation of a core domain in metazoan p300/CBP acetyltransferase-related proteins
Nucleic Acids Res., February 1, 2001; 29(3): 589 - 597.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
C.-J. Chen, Z. Deng, A. Y. Kim, G. A. Blobel, and P. M. Lieberman
Stimulation of CREB Binding Protein Nucleosomal Histone Acetyltransferase Activity by a Class of Transcriptional Activators
Mol. Cell. Biol., January 15, 2001; 21(2): 476 - 487.
[Abstract] [Full Text]

Home page
 Mol. Cell. Biol.Home page
R. Bayly and D. P. LeBrun
Role for Homodimerization in Growth Deregulation by E2a Fusion Proteins
Mol. Cell. Biol., August 15, 2000; 20(16): 5789 - 5796.
[Abstract] [Full Text]

Home page
 Genes Dev.Home page
R. H. Goodman and S. Smolik
CBP/p300 in cell growth, transformation, and development
Genes & Dev., July 1, 2000; 14(13): 1553 - 1577.
[Full Text]

Home page
 J. Biol. Chem.Home page
S. Iwamoto, H. Suganuma, T. Kamesaki, T. Omi, H. Okuda, and E. Kajii
Cloning and Characterization of Erythroid-specific DNase I-hypersensitive Site in Human Rhesus-associated Glycoprotein Gene
J. Biol. Chem., August 25, 2000; 275(35): 27324 - 27331.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. A. Pise-Masison, R. Mahieux, M. Radonovich, H. Jiang, and J. N. Brady
Human T-lymphotropic Virus Type I Tax Protein Utilizes Distinct Pathways for p53 Inhibition That Are Cell Type-dependent
J. Biol. Chem., January 5, 2001; 276(1): 200 - 205.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H.-L. Hung, A. Y. Kim, W. Hong, C. Rakowski, and G. A. Blobel
Stimulation of NF-E2 DNA Binding by CREB-binding Protein (CBP)-mediated Acetylation
J. Biol. Chem., March 30, 2001; 276(14): 10715 - 10721.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blobel, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blobel, G. A.
Related Collections
Right arrow Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020